trending Market Intelligence /marketintelligence/en/news-insights/trending/f3GH5eGIqZEkF5p1hy5GpA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

IMV raises C$29.5M via common stock offering to fund cancer drug programs

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


IMV raises C$29.5M via common stock offering to fund cancer drug programs

IMV Inc. raised about C$29.5 million from a common stock offering to fund the development of its cancer drug programs.

The Dartmouth, Nova Scotia-based immuno-oncology company said the underwriters partially exercised their overallotment option to buy an additional 504,855 common shares at C$5.45 apiece to raise about C$2.75 million. The company offered 4.9 million shares at C$5.45 per share to raise about C$26.7 million in gross proceeds.

IMV plans to use the net proceeds to advance the experimental cancer technology DPX-Survivac — designed to deliver medicines into the system in longer-lasting, oil-protected particles. The treatment is being evaluated in phase 2 studies with Merck & Co. Inc.'s blockbuster medicine Keytruda to treat certain types of cancers, such as bladder, liver, ovarian or non-small-cell lung cancers.

The funds will also be used for general corporate purposes.

Wells Fargo Securities and Raymond James served as joint book-running managers, while B. Riley FBR acted as co-manager for the offering.